Angiotensin IV analogue
Also called Dihexa acetate, PNB-0408
Dihexa is a peptide — a short chain of amino acids. It is not an approved medicine. Products sold online labelled “for research use only” are not checked by FDA for what they contain.
Every claim about Dihexa will sit in exactly one of these boxes, so you can see how strong it is:
The sorted list of claims hasn't passed scientific review yet, so we don't show it. Why?
A simple explanation of how it works hasn't passed scientific review yet, so we don't show it. Why?
Each study will show its type, size, who was studied, what was found, its limits, its date and a link to the original.
The study list hasn't passed scientific review yet, so we don't show it. Why?
For unapproved compounds, the honest answer is usually that long-term safety in people is unknown.
A sourced safety summary hasn't passed scientific review yet, so we don't show it. Why?
Not approved. FDA reviews and advisory votes are steps in a process — only an FDA approval means a product is approved.
Compounding list
FDA published a notice scheduling a Pharmacy Compounding Advisory Committee meeting and said it would remove twelve peptides from Category 2 of its interim 503A bulks list after nominators withdrew their nominations.
What this doesn't mean: Removal from Category 2 does not make a substance eligible for compounding, and it is not FDA approval.
Under review
FDA indicated that Cathelicidin LL-37, Dihexa, GHK-Cu (injectable), PEG-MGF and Melanotan II would be considered before the end of February 2027.
What this doesn't mean: Scheduled, not decided. Nothing about these substances' status has changed yet.
Publications from PubMed and registered trials from ClinicalTrials.gov, each linked so you can check it yourself.
The reference list hasn't passed scientific review yet, so we don't show it. Why?